As one of our resident wardrobe-basics experts, I’ve learned that a good white T-shirt is easy to find, but a truly great one — one that hits the marks on comfort and durability as well as ...

Tara Bancroft’s rating is based on the promising potential of TG Therapeutics’ Briumvi in the anti-CD20 relapsing multiple sclerosis (RMS) market. Briumvi has shown remarkable efficacy with an ...

TG Therapeutics' Q3 earnings missed EPS expectations, primarily due to higher non-cash compensation and increased R&D investments, despite Briumvi's revenue growth. Briumvi, a CD20-directed ...

When you buy through our links, Business Insider may earn an affiliate commission. Learn more T-shirts are quintessential for any wardrobe, especially during the spring and summer. They're a ...

U.S. net revenue from Briumvi grew by more than 230% year over year to $83.3 million. Total revenue for Q3 of $83.9 million surpassed analysts' expectations of $81.7 million. Diluted earnings per ...

October 2024 A button-up shirt has undeniable utility: It’s the rare garment that’s equally well suited for work, special occasions, and the farmers market. But finding one that’s right for ...

TG Therapeutics, Inc. reported a modest Q3 beat and raised the full-year net sales guidance range for Briumvi by $7.5 million at the mid-point. The results were slightly underwhelming but ...

Third quarter 2024 U.S. BRIUMVI net revenue of $83.3 million Raises full year 2024 U.S. BRIUMVI net revenue target to $300 - $305 million Conference call to be held today, November 4, 2024 ...

TG Therapeutics reported Q3 results, including “solid” Briumvi U.S. net product revenue up $83.3M, up 15% quarter over quarter, the analyst tells investors in a research note. The firm ...

Michael S. Weiss, the Company’s Chairman and Chief Executive Officer stated, “The positive feedback and uptake of BRIUMVI in the marketplace continues to outpace our expectations and we are ...

NEW YORK, Nov. 04, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) (the Company or TG Therapeutics) today announced its financial results for the third quarter of 2024, along with ...